Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

778
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
778
Overview of Exosomes01:36

Overview of Exosomes

3.0K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.0K
Cancer Vaccines01:30

Cancer Vaccines

581
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
581

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How Host Phylogeny, Diet, and Habitat Affect Gut Microbial Diversity in Wild Snakes.

Ecology and evolution·2026
Same author

Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA Group.

American journal of hematology·2026
Same author

Identification and Validation of miR-206-3p Targeting WT-1 Promotes Membranous Nephropathy Through a Comprehensive Bioinformatics and Machine Learning Algorithm.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Tim-3-targeted vaccines overcome tumor immunosuppression and reduce cDC1 dependence to elicit potent anti-tumor immunity.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

The membrane-associated ubiquitin ligase MARCHF8 degrades MHC-I in HPV-positive head and neck cancer for immune evasion.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Unraveling the Epigenetic Regulation of Regulatory T Cells in Cancer Immunity.

Cells·2026

Related Experiment Video

Updated: Oct 25, 2025

Preparation of Exosomes for siRNA Delivery to Cancer Cells
09:59

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Published on: December 5, 2018

25.5K

DC-Derived Exosomes for Cancer Immunotherapy.

Yi Yao1,2, Chunmei Fu1, Li Zhou1,2

  • 1Center for Cutaneous Biology and Immunology, Department of Dermatology, Henry Ford Health System, Detroit, MI 48202, USA.

Cancers
|August 7, 2021
PubMed
Summary

DC-derived exosomes (DCexos) show promise for cancer immunotherapy but face challenges. Further research into DCexos, particularly those derived from specific dendritic cell types, is needed to improve clinical efficacy against tumors.

Keywords:
cancer immunotherapydendritic cellsexosomesplasmacytoid DCsvaccines

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.8K
Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes
09:30

Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes

Published on: May 24, 2019

7.6K

Related Experiment Videos

Last Updated: Oct 25, 2025

Preparation of Exosomes for siRNA Delivery to Cancer Cells
09:59

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Published on: December 5, 2018

25.5K
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.8K
Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes
09:30

Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes

Published on: May 24, 2019

7.6K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Dendritic cells (DCs) are crucial for initiating adaptive immunity and regulating anti-tumor responses.
  • DC-based vaccines are a promising cancer immunotherapy, but clinical success is limited by tumor immunosuppression.
  • Type 1 conventional DCs (cDC1s) are critical for cross-priming CD8 T cells and anti-tumor efficacy.

Purpose of the Study:

  • To review the potential of DC-derived exosomes (DCexos) as an alternative to DC-based vaccines for cancer immunotherapy.
  • To address the limitations of current DCexo vaccines in clinical trials and propose future research directions.
  • To explore strategies for enhancing DCexo vaccine efficacy, particularly concerning the source of DCs and antigen loading.

Main Methods:

  • Review of current literature on DC-based vaccines, DCexos, and cancer immunotherapy.
  • Analysis of pre-clinical and clinical trial data for DCexo vaccines.
  • Discussion of the role of cDC1s and alternative DC sources in DCexo generation.

Main Results:

  • DCexos are more resistant to tumor-mediated immunosuppression than DC-based vaccines.
  • Pre-clinical studies show better anti-tumor efficacy with DCexo vaccines.
  • Clinical trials of DCexo vaccines have shown limited efficacy and failed to induce tumor-specific T cell responses.

Conclusions:

  • Current DCexo vaccines, often using peptide-loaded exosomes from monocyte-derived DCs, have limitations.
  • Further research is needed to optimize DCexo vaccine design, including exploring different DC subsets like cDC1s.
  • Expanding DCexo research is crucial to realize their full potential in cancer immunotherapy.